EUVIMEDEUVIMED entdecken
Kohortenstudie

Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study

Takahito Sugase iD, Takashi Kanemura, Norihiro Matsuura, Tomohira Takeoka, Yuki Ushimaru, Yasunori Masuike, Yoshitomo Yanagimoto, Kazuyoshi Yamamoto, Takeshi Omori, Ryota Mori, Masatoshi Kitakaze, Masahiko Kubo und 8 weitere

Esophagus · 2025-10 · 22 (4) · 565-573

DOI: 10.1007/s10388-025-01137-4 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Esophagus, online erschienen am 08.06.2025. Verfasst von Takahito Sugase und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, 541-8567, Japan. Hauptthemen laut MEDLINE: Nivolumab, Esophageal Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Nivolumab, approved for adjuvant therapy in resected esophageal cancer, is typically administered at 240 mg every 2 weeks (Q2W) or 480 mg every 4 weeks (Q4W). However, data on the 480 mg Q4W regimen as an initial therapy are limited. In this study, we evaluated its safety and efficacy. METHODS: This prospective cohort study included 50 patients with pathologically confirmed lymph node metastases who underwent radical esophagectomy following preoperative therapy. All patients received at least one dose of nivolumab (480 mg Q4W). The primary endpoint was the incidence of Grade 3 or higher nivolumab-related adverse events (AEs). RESULTS: Of the cohort, 88% (44/50) received preoperative chemotherapy. The pathological lymph node status was distributed as follows: ypN1 (42%), ypN2 (40%), and ypN3 (18%). A total of 26 patients (52%) completed one year of therapy. Therapy discontinuation occurred because of relapse (30%), nivolumab-related AEs (10%), or patient preference (8%). Nivolumab-related AEs occurred in 70% of the patients, with Grade 3 or higher AEs occurring in 8%. The most common AEs were skin-related reactions (30%), elevated aspartate aminotransferase levels (24%), fatigue (12%), hypothyroidism (12%), and hyperthyroidism (10%). The majority of AEs occurred during the first four cycles, whereas thyroid dysfunction, arthritis, and pulmonary AEs appeared even later. One- and two-year disease-free survival (DFS) rates were 78.0% and 52.2%, respectively. Patients aged < 65 years and those with ypN2 disease demonstrated better DFS. CONCLUSION: Adjuvant nivolumab 480 mg Q4W may represent a potential treatment option with a manageable safety profile and favorable short-term DFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabEsophageal NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleFemaleAgedProspective StudiesMiddle AgedEsophagectomyChemotherapy, AdjuvantLymphatic MetastasisTreatment OutcomeDrug Administration ScheduleAdult

Stichwörter der Autor:innen

4-week dosingAdjuvant nivolumab therapyAdverse eventsDisease-free survivalEsophageal cancer

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, 541-8567, Japan.
  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, 541-8567, Japan. hiroshi.miyata@oici.jp.

ORCID-Profile: Takahito Sugase

Zitieren

APA

Sugase, T., Kanemura, T., Matsuura, N., Takeoka, T., Ushimaru, Y., Masuike, Y., Yanagimoto, Y., Yamamoto, K., Omori, T., Mori, R., Kitakaze, M., Kubo, M., Mukai, Y., Komatsu, H., Sueda, T., Kagawa, Y., Wada, H., Goto, K., Yasui, M., & Miyata, H. (2025). Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study. Esophagus, 22(4), 565-573. https://doi.org/10.1007/s10388-025-01137-4

Vancouver

Sugase T, Kanemura T, Matsuura N, Takeoka T, Ushimaru Y, Masuike Y, et al. Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study. Esophagus. 2025;22(4):565-573. doi:10.1007/s10388-025-01137-4

BibTeX
@article{Sugase2025,
  author = {Sugase, Takahito and Kanemura, Takashi and Matsuura, Norihiro and Takeoka, Tomohira and Ushimaru, Yuki and Masuike, Yasunori and Yanagimoto, Yoshitomo and Yamamoto, Kazuyoshi and Omori, Takeshi and Mori, Ryota and Kitakaze, Masatoshi and Kubo, Masahiko and Mukai, Yosuke and Komatsu, Hisateru and Sueda, Toshinori and Kagawa, Yoshinori and Wada, Hiroshi and Goto, Kunihito and Yasui, Masayoshi and Miyata, Hiroshi},
  title = {Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study},
  journal = {Esophagus},
  year = {2025},
  volume = {22},
  number = {4},
  pages = {565--573},
  doi = {10.1007/s10388-025-01137-4}
}
Kostenlos starten →